Current market catalysts

CoreWeave And Parallel Works Announce Deployment Of Managed AI, High-Performance Computing Platform For DARPA NODES Program On NVIDIA HGX H100 Systems; Terms Not Disclosed

Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230

$100 Invested In Vertiv Holdings 5 Years Ago Would Be Worth This Much Today

Vertiv Holdings (NYSE:VRT) has outperformed the market over the past 5 years by 51.87% on an annualized basis producing an average annual return of 63.32%. Currently, Vertiv Holdings has a market capitalization of

Texas Rep. Lloyd Doggett Bought Over $1K Worth of Procter & Gamble Stock: Here’s What You Should Know

Records from September 8, 2026 indicate that Representative Lloyd Doggett of Texas made a purchase of Procter & Gamble (NYSE:PG), valued between $1,001 and $15,000, with the transaction dated August 17, 2026 and

Stifel Maintains Hold on Paychex, Raises Price Target to $130

Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15

Stifel Maintains Hold on Adobe, Raises Price Target to $225

Dell Technologies shares are trading higher following reports suggesting the company wants to raise $4 billion from a bond sale.

Centerspace shares are trading higher after the company announced it entered into a definitive merger with Independence Realty Trust, under which Centerspace and IRT will combine in an all-stock transaction. The combined company is expected to have a pro forma equity market capitalization of approximately $5.0 billion and a total enterprise value of approximately $8.1 billion.

JP Morgan Assumes Lithium Americas at Overweight, Announces Price Target of C$8

AbbVie Exec Says Balance Sheet And Growth Runway Allow Company To Consider Both Early- And Late-Stage Business Development Opportunities

Oppenheimer Maintains Outperform on Zurn Elkay Water Solns, Raises Price Target to $60

UnitedHealth Group shares are trading lower. A report suggested the company sold its interest in Florida WellMed clinics to TPG.

Oppenheimer Maintains Outperform on Ralliant, Raises Price Target to $80

AdaptHealth shares are trading lower. The company appointed Harriss T. Currie as its Chief Financial Officer.

Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says

Opus Genetics posts positive Phase 1/2 trial results for OPGx-BEST1 and aligns with the FDA on Phase 3 plans for 2027.

HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target

GameChange Energy Says Subsidiary GameChange Solar Filed Patent Infringement Lawsuit Against Nextpower Over High-Tilt Stow Technology, Seeking Injunctive Relief And Damages

JP Morgan Assumes Lithium Americas at Overweight, Announces Price Target of $6

Democratic Senators Urge Delta Air Lines In A Letter To Remain Neutral In Flight Attendant Union Organizing Effort

$1000 Invested In Equinix 15 Years Ago Would Be Worth This Much Today

Equinix (NASDAQ:EQIX) has outperformed the market over the past 15 years by 4.2% on an annualized basis producing an average annual return of 17.24%. Currently, Equinix has a market capitalization of $102.74 billion.

Jersey Mike’s Subs shares are trading higher despite reporting a year-over-year decrease in its Q2 net income and worse-than-expected Q2 sales results. The company's CEO said that traffic is accelerating despite industrywide weakness, supporting Q2 same-store sales growth of 2.3% year-over-year.

Barnes & Noble Education shares are trading lower after the company reported worse-than-expected Q1 financial results.

Oppenheimer Maintains Outperform on IDEX, Raises Price Target to $270

Elon Musk Spooked Howmet. GE Just Validated the Bull Case

Elon Musk's SpaceX plans and GE's $11.75B deal suggest turbine blade shortages remain one of aerospace's biggest bottlenecks.

BridgeBio Oncology Therapeutics shares are trading lower after the company announced new clinical data for KRASG12C inhibitor BBO-8520.

Memory Is the New ‘King’ of Chips, Taking Over 50% of Semiconductor Revenue, Susquehanna Says

Susquehanna says memory now drives 50%-55% of semiconductor revenue as AI demand reshapes chip spending and boosts Micron.

Oppenheimer Maintains Outperform on Ormat Technologies, Raises Price Target to $145

TD Cowen Maintains Hold on Amphenol, Lowers Price Target to $90

TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $55